These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

618 related articles for article (PubMed ID: 18759549)

  • 1. Therapy of X-linked adrenoleukodystrophy.
    Semmler A; Köhler W; Jung HH; Weller M; Linnebank M
    Expert Rev Neurother; 2008 Sep; 8(9):1367-79. PubMed ID: 18759549
    [TBL] [Abstract][Full Text] [Related]  

  • 2. X-linked adrenoleukodystrophy.
    Moser HW; Mahmood A; Raymond GV
    Nat Clin Pract Neurol; 2007 Mar; 3(3):140-51. PubMed ID: 17342190
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of Lorenzo's oil on oxidative stress in X-linked adrenoleukodystrophy.
    Deon M; Wajner M; Sirtori LR; Fitarelli D; Coelho DM; Sitta A; Barschak AG; Ferreira GC; Haeser A; Giugliani R; Vargas CR
    J Neurol Sci; 2006 Sep; 247(2):157-64. PubMed ID: 16750542
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elongation of very long-chain fatty acids is enhanced in X-linked adrenoleukodystrophy.
    Kemp S; Valianpour F; Denis S; Ofman R; Sanders RJ; Mooyer P; Barth PG; Wanders RJ
    Mol Genet Metab; 2005 Feb; 84(2):144-51. PubMed ID: 15670720
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progression of abnormalities in adrenomyeloneuropathy and neurologically asymptomatic X-linked adrenoleukodystrophy despite treatment with "Lorenzo's oil".
    van Geel BM; Assies J; Haverkort EB; Koelman JH; Verbeeten B; Wanders RJ; Barth PG
    J Neurol Neurosurg Psychiatry; 1999 Sep; 67(3):290-9. PubMed ID: 10449548
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Endocrine disease in adrenoleukodystrophy].
    Girard S; Bruckert E; Turpin G
    Ann Med Interne (Paris); 2001 Feb; 152(1):15-26. PubMed ID: 11240421
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A two-year trial of oleic and erucic acids ("Lorenzo's oil") as treatment for adrenomyeloneuropathy.
    Aubourg P; Adamsbaum C; Lavallard-Rousseau MC; Rocchiccioli F; Cartier N; Jambaqué I; Jakobezak C; Lemaitre A; Boureau F; Wolf C
    N Engl J Med; 1993 Sep; 329(11):745-52. PubMed ID: 8350883
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early oxidative damage underlying neurodegeneration in X-adrenoleukodystrophy.
    Fourcade S; López-Erauskin J; Galino J; Duval C; Naudi A; Jove M; Kemp S; Villarroya F; Ferrer I; Pamplona R; Portero-Otin M; Pujol A
    Hum Mol Genet; 2008 Jun; 17(12):1762-73. PubMed ID: 18344354
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Examination of very long chain fatty acids in diagnosis of x-linked adrenoleukodystrophy].
    Stradomska TJ; Tylki-Szymańska A
    Pediatr Pol; 1996 Mar; 71(3):197-201. PubMed ID: 8966090
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [X-linked adrenoleukodystrophy--2 case reports].
    Dumić M; Ille J; Plavsić V; Filipović-Grcić B; Vrljicak K; Barisić N; Roscher A
    Lijec Vjesn; 1998; 120(1-2):19-23. PubMed ID: 9650481
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lorenzo's oil and platelet activation in adrenomyeloneuropathy and asymptomatic X-linked adrenoleukodystrophy.
    Konijnenberg A; van Geel BM; Sturk A; Schaap MC; von dem Borne AE; de Bruijne-Admiraal LG; Schutgens RB; Assies J; Barth PG
    Platelets; 1998; 9(1):41-8. PubMed ID: 16793744
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is subclinical adrenal failure in adrenoleukodystrophy/adrenomyeloneuropathy reversible?
    Cappa M; Bizzarri C; Giannone G; Aiello C; Di Biase A
    J Endocrinol Invest; 2011 Nov; 34(10):753-6. PubMed ID: 21399389
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and therapeutic aspects of adrenoleukodystrophy and adrenomyeloneuropathy.
    Moser HW
    J Neuropathol Exp Neurol; 1995 Sep; 54(5):740-5. PubMed ID: 7666063
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of pharmacological induction of fatty acid beta-oxidation in X-linked adrenoleukodystrophy.
    McGuinness MC; Zhang HP; Smith KD
    Mol Genet Metab; 2001; 74(1-2):256-63. PubMed ID: 11592822
    [TBL] [Abstract][Full Text] [Related]  

  • 15. X-Linked adrenoleukodystrophy: overview and prognosis as a function of age and brain magnetic resonance imaging abnormality. A study involving 372 patients.
    Moser HW; Loes DJ; Melhem ER; Raymond GV; Bezman L; Cox CS; Lu SE
    Neuropediatrics; 2000 Oct; 31(5):227-39. PubMed ID: 11204280
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [X-linked adrenoleukodystrophy].
    Aubourg P
    Ann Endocrinol (Paris); 2007 Dec; 68(6):403-11. PubMed ID: 17532287
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current and future pharmacological treatment strategies in X-linked adrenoleukodystrophy.
    Berger J; Pujol A; Aubourg P; Forss-Petter S
    Brain Pathol; 2010 Jul; 20(4):845-56. PubMed ID: 20626746
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapy of X-linked adrenoleukodystrophy.
    Moser HW
    NeuroRx; 2006 Apr; 3(2):246-53. PubMed ID: 16554262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induced pluripotent stem cell models from X-linked adrenoleukodystrophy patients.
    Jang J; Kang HC; Kim HS; Kim JY; Huh YJ; Kim DS; Yoo JE; Lee JA; Lim B; Lee J; Yoon TM; Park IH; Hwang DY; Daley GQ; Kim DW
    Ann Neurol; 2011 Sep; 70(3):402-9. PubMed ID: 21721033
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 31.